ReviewUrologie (Heidelberg, Germany)2026
[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].
Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravesical Bacillus Calmette-Guerin (BCG) therapy following transurethral resection (TURBT) remains an important standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC). Recent phase III trials have evaluated the addition of immune checkpoint inhibitors (IO) to further reduce recurrence rates.
methodsThis review synthesizes data from the CREST (sasanlimab), POTOMAC (durvalumab), and ALBAN (atezolizumab) trials, focusing on surgical quality, BCG maintenance duration, and primary endpoint definitions.
resultsCREST and POTOMAC demonstrated significant improvements in event-free or disease-free survival (both hazard ratio [HR] 0.68) when a 2-year BCG maintenance schedule was followed. In contrast, the ALBAN trial (HR 0.98) failed its primary endpoint. Key reasons for this discrepancy include the shortened BCG maintenance (1 year) and the inclusion of low-grade recurrences in the primary endpoint, which by international consensus do not constitute BCG failure. Data also show that IO cannot compensate for the omission of BCG maintenance. Severe systemic toxicity (grade 3-5) increased substantially with the combination therapy (up to 29%).
conclusionCombination therapy strictly necessitates the full BCG maintenance schedule. Given the significant systemic toxicity and the current lack of a demonstrated overall survival benefit, careful patient selection is mandatory.
Indexed as
Identifiers
42697960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.